Literature DB >> 1624628

Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy.

M K Silverman1, A W Kopf, A H Gladstein, R S Bart, C M Grin, M J Levenstein.   

Abstract

This is the fourth report in a series that reviews the experience in the Skin and Cancer Unit, from 1955 through 1982, with the treatment of basal cell carcinomas (BCCs). It concerns 862 primary (previously untreated) BCCs irradiated by a "standardized" x-ray therapy schedule. The overall 5-year recurrence rate for these lesions, as determined by the modified life-table method, was 7.4%. This rate was not significantly different from that experienced with 211 recurrent (previously treated) BCCs with a re-recurrence rate of 9.5% (P = .552). For the primary BCCs, multivariate analysis showed that increasing BCC diameter was the only independent risk factor for high recurrence rates (P = .003). The patient's age or sex, the duration of the BCC, the anatomic site of the BCC, or time-span treated (1955-1963, 1964-1972, 1973-1982) did not significantly affect the recurrence rate. Additional analysis showed that BCCs on the head less than 10 mm in diameter had a 5-year recurrence rate of 4.4% whereas those 10 mm or greater in diameter had a rate of 9.5%. Lastly, the proportion of recurrence-free treatment sites with a good or excellent long-term cosmetic outcome after x-ray therapy (63%) was lower than previous reports in this series with curettage-electrodesiccation (91%) and surgical excision (84%). Thus, if the long-term cosmetic outcome after treatment is not an overriding concern to the patient, x-ray therapy is an effective modality for many primary and recurrent BCCs.

Entities:  

Mesh:

Year:  1992        PMID: 1624628     DOI: 10.1111/j.1524-4725.1992.tb03508.x

Source DB:  PubMed          Journal:  J Dermatol Surg Oncol        ISSN: 0148-0812


  13 in total

Review 1.  Basal cell carcinoma.

Authors:  C S M Wong; R C Strange; J T Lear
Journal:  BMJ       Date:  2003-10-04

Review 2.  Diagnosis and Management of Basal Cell Carcinoma.

Authors:  Keiji Tanese
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

3.  A reliable frozen section technique for basal cell carcinomas of the head and neck.

Authors:  Wisam Menesi; Edward W Buchel; Thomas Je Hayakawa
Journal:  Plast Surg (Oakv)       Date:  2014       Impact factor: 0.947

4.  Systemic therapy for inoperable and metastatic basal cell cancer.

Authors:  Leslie A Fecher
Journal:  Curr Treat Options Oncol       Date:  2013-06

Review 5.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Oculoplastic aspects of ocular oncology.

Authors:  C Rene
Journal:  Eye (Lond)       Date:  2012-11-30       Impact factor: 3.775

7.  Nonmelanoma skin cancer.

Authors:  Venura Samarasinghe; Vishal Madan
Journal:  J Cutan Aesthet Surg       Date:  2012-01

8.  Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study.

Authors:  M F Avril; A Auperin; A Margulis; A Gerbaulet; P Duvillard; E Benhamou; J C Guillaume; R Chalon; J Y Petit; H Sancho-Garnier; M Prade; J Bouzy; D Chassagne
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 9.  Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management.

Authors:  Alexander G Marzuka; Samuel E Book
Journal:  Yale J Biol Med       Date:  2015-06-01

10.  Basal cell carcinoma: 10-year experience with electrochemotherapy.

Authors:  Luca G Campana; Roberto Marconato; Sara Valpione; Sara Galuppo; Mauro Alaibac; Carlo R Rossi; Simone Mocellin
Journal:  J Transl Med       Date:  2017-05-31       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.